{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:01:31Z","timestamp":1761919291555},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,1,8]],"date-time":"2010-01-08T00:00:00Z","timestamp":1262908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s00415-009-5442-6","type":"journal-article","created":{"date-parts":[[2010,1,7]],"date-time":"2010-01-07T12:54:07Z","timestamp":1262868847000},"page":"937-946","source":"Crossref","is-referenced-by-count":23,"title":["3,4-Diaminopyridine safety in clinical practice: an observational, retrospective cohort study"],"prefix":"10.1007","volume":"257","author":[{"given":"Laurent","family":"Flet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Polard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Guillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Leray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Allain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Javaudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Edan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,1,8]]},"reference":[{"key":"5442_CR1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0022-510X(96)00012-3","volume":"138","author":"ML Aisen","year":"1996","unstructured":"Aisen ML, Sevilla D, Edelstein L, Blass J (1996) A double-blind placebo-controlled study of 3,4-diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit. J Neurol Sci 138:93\u201396","journal-title":"J Neurol Sci"},{"key":"5442_CR2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/13524585070130030101","volume":"13","author":"AG Beiske","year":"2007","unstructured":"Beiske AG, Naess H, Aarseth JH, Andersen O, Elovaara I, Farkkila M, Hansen HJ, Mellgren SI, Sandberg-Wollheim M, Sorensen PS, Myhr KM (2007) Health-related quality of life in secondary progressive multiple sclerosis. Mult Scler 13:386\u2013392","journal-title":"Mult Scler"},{"key":"5442_CR3","first-page":"256","volume":"32","author":"FW Bertelsmann","year":"1992","unstructured":"Bertelsmann FW, Polman CH, Van Diemen HAM et al (1992) A comparison between 4-aminopyridine and 3,4-diaminopyridine in the treatment of multiple sclerosis. Ann Neurol 32:256","journal-title":"Ann Neurol"},{"key":"5442_CR4","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1002\/ana.410360728","volume":"36","author":"CT Bever","year":"1994","unstructured":"Bever CT (1994) The current status of studies of aminopyridines in patients with multiple sclerosis. Ann Neurol 36:S118\u2013S121","journal-title":"Ann Neurol"},{"key":"5442_CR5","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1212\/WNL.47.6.1457","volume":"47","author":"CT Bever","year":"1996","unstructured":"Bever CT, Anderson PA, Leslie J, Panitch HS, Dhib-Jaibut S, Khan OA, Milo R, Hebel JR, Conway KL, Katz E, Johnson KP (1996) Treatment with oral 3,4-diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 47:1457\u20131462","journal-title":"Neurology"},{"key":"5442_CR6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ana.410270411","volume":"27","author":"CT Bever","year":"1990","unstructured":"Bever CT, Leslie J, Camenga DL, Panitch HS, Johnson KP (1990) Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Ann Neurol 27:421\u2013427","journal-title":"Ann Neurol"},{"key":"5442_CR7","unstructured":"Agence Fran\u00e7aise de S\u00e9curit\u00e9 Sanitaire des Produits de Sant\u00e9 (AFSSaPS) (2005) Bonnes Pratiques de Pharmacovigilance. Available at: http:\/\/www.afssaps.fr\/Activites\/Pharmacovigilance\/Textes-reglementaires-de-la-Pharmacovigilance\/(offset)\/7 . Accessed 4 Jan 2010"},{"key":"5442_CR8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ana.410340118","volume":"34","author":"JL Carter","year":"1993","unstructured":"Carter JL, Stevens JC, Smith B et al (1993) A double-blind, placebo-controlled crossover trial of 3,4-diaminopyridine in the symptomatic treatment of multiple sclerosis. Ann Neurol 34:108","journal-title":"Ann Neurol"},{"key":"5442_CR9","first-page":"354","volume":"192","author":"B Casanova","year":"1993","unstructured":"Casanova B, Vilchez JJ, Rubio P (1993) The treatment of the Eaton-Lambert myasthenic syndrome with 3,4-diaminopyridine. Rev Clin Esp 192:354\u2013355","journal-title":"Rev Clin Esp"},{"key":"5442_CR10","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1002\/ana.410360733","volume":"36","author":"C Confavreux","year":"1994","unstructured":"Confavreux C (1994) Establishment and use of multiple sclerosis registers: EDMUS. Ann Neurol 36:S136\u2013S139","journal-title":"Ann Neurol"},{"key":"5442_CR11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.55.8.671","volume":"55","author":"C Confavreux","year":"1992","unstructured":"Confavreux C, Compston DA, Hommes OR, Mc Donald WI, Thompson AJ (1992) EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatr 55:671\u2013676","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"5442_CR12","unstructured":"Curti C, Feuillet L, Villano P, Pelletier J, Gensollen S, Timon David P, Bongrand MC (2004) Tolerance and efficacy of 3,4-diaminopyridine in patients suffering from multiple sclerosis. In: 2nd American College of Clinical Pharmacy\u2014European Society of Clinical Pharmacy joint meeting, Paris, 28\u201330 May"},{"key":"5442_CR13","unstructured":"Demolis JL, Acar V, Raphael M, Goulay-Dufay S, Pradeau D, Funck-Brentano C (2005) Study on the bioequivalence of 3,4-diaminopyridine base and 3,4-diaminopyridine salt. Fundam Clin Pharmacol 19:220"},{"key":"5442_CR14","unstructured":"(2003) Deutscher arzneimittel-codex. Deutscher Apotheker Verlag, Stuttgart"},{"key":"5442_CR15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00002018-199410020-00001","volume":"10","author":"IR Edwards","year":"1994","unstructured":"Edwards IR, Biriell C (1994) Harmonisation in pharmacovigilance. Drug Saf 10:93\u2013102","journal-title":"Drug Saf"},{"key":"5442_CR16","unstructured":"EMEA Committee for Orphan Medicinal Products (2003) Public summary of positive opinion for orphan designation of 3,4-diaminopyridine phosphate for the treatment of Lambert-Eaton myasthenic syndrome. London, 29 Jan. EMEA\/COMP\/2732\/02"},{"key":"5442_CR17","unstructured":"Jost WH, Mielke U, Forrett-Kaminsky MC, Schimrigk K (1992) Long-term treatment of Lambert-Eaton syndrome by 3,4-diaminopyridine. Rev Neurol (Paris) 148:776\u2013779"},{"key":"5442_CR18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.pharmthera.2005.10.006","volume":"111","author":"SI Judge","year":"2006","unstructured":"Judge SI, Bever CT (2006) Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 111:224\u2013259","journal-title":"Pharmacol Ther"},{"key":"5442_CR19","doi-asserted-by":"crossref","unstructured":"Kanzato N, Motomura M, Suehara M, Arimura K (1999) Lambert-Eaton myasthenic syndrome with ophtalmoparesis and pseudoblepharospasm. Muscle Nerve 22:1727\u20131730","DOI":"10.1002\/(SICI)1097-4598(199912)22:12<1727::AID-MUS19>3.0.CO;2-K"},{"key":"5442_CR20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/1545968306298934","volume":"22","author":"D Kos","year":"2008","unstructured":"Kos D, Kerckhofs E, Nagels G, D\u2019hooghe MB, Ilsbroukx S (2008) Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair 22:91\u2013100","journal-title":"Neurorehabil Neural Repair"},{"key":"5442_CR21","first-page":"345","volume":"26","author":"P Lechat","year":"1968","unstructured":"Lechat P, Deysson G, Lemeignan M et al (1968) Comparison of acute toxicity of some aminopyridines in vivo (mice) and in vitro (tissue culture). Ann Pharm Fr 26:345\u2013349","journal-title":"Ann Pharm Fr"},{"key":"5442_CR22","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1212\/01.wnl.0000218297.90054.28","volume":"66","author":"D Lorenz","year":"2006","unstructured":"Lorenz D, Hagen K, Ufer M, Cascorbi I, Deuschl G, Volkmann J (2006) No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study. Neurology 66:1753\u20131755","journal-title":"Neurology"},{"key":"5442_CR23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0404.1993.tb04205.x","volume":"88","author":"H Lundh","year":"1993","unstructured":"Lundh H, Nilsson O, Ros\u00e9n I, Johansson S (1993) Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol Scand 88:136\u2013140","journal-title":"Acta Neurol Scand"},{"key":"5442_CR24","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","volume":"321","author":"KM McEvoy","year":"1989","unstructured":"McEvoy KM, Windebank AJ, Dauber JR, Low PA (1989) 3,4-diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 321:1567\u20131571","journal-title":"N Engl J Med"},{"key":"5442_CR25","unstructured":"Murray NMF, Newsom-Davis J, Karni Y, Wiles CM (1984) Oral 3,4-diaminopyridine in the treatment of the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 47:1052\u20131053"},{"key":"5442_CR26","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/WNL.34.4.480","volume":"34","author":"J Newsom-Davis","year":"1984","unstructured":"Newsom-Davis J, Murray NM (1984) Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 34:480\u2013485","journal-title":"Neurology"},{"key":"5442_CR27","doi-asserted-by":"crossref","unstructured":"Palace J, Wiles CM, Newsom-Davis J (1991) 3,4-diaminopyridine in the treatment of congenital (hereditary) myasthenia. J Neurol Neurosurg Psychiatry 54:1069\u20131072","DOI":"10.1136\/jnnp.54.12.1069"},{"key":"5442_CR28","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1345\/aph.1G166","volume":"40","author":"A Pelufo-Pellicer","year":"2006","unstructured":"Pelufo-Pellicer A, Monte-Boquet E, Roma-Sanchez E, Casanova-Sorni C, Poveda-Andres JL (2006) Fetal exposure to 3,4-diaminopyridine in a pregnant woman with congenital myasthenia syndrome. Ann Pharmacother 40:762\u2013766","journal-title":"Ann Pharmacother"},{"key":"5442_CR29","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/archneur.1994.00540230074016","volume":"51","author":"CH Polman","year":"1994","unstructured":"Polman CH, Bertelsmann FW, de Waal R, van Diemen HA, Uitdehaag BM, van Loenen AC, Koetsier JC (1994) 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 51:1136\u20131139","journal-title":"Arch Neurol"},{"key":"5442_CR30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1749-6632.1998.tb11022.x","volume":"841","author":"DB Sanders","year":"1998","unstructured":"Sanders DB (1998) 3,4-diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Ann N Y Acad Sci 841:811\u2013816","journal-title":"Ann N Y Acad Sci"},{"key":"5442_CR31","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1749-6632.1993.tb22949.x","volume":"681","author":"DB Sanders","year":"1993","unstructured":"Sanders DB, Howard JF, Massey JM (1993) 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis. Ann N Y Acad Sci 681:588\u2013590","journal-title":"Ann N Y Acad Sci"},{"key":"5442_CR32","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","volume":"54","author":"DB Sanders","year":"2000","unstructured":"Sanders DB, Massey JM, Sanders LL, Edwards LJ (2000) A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 54:603\u2013607","journal-title":"Neurology"},{"key":"5442_CR33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF01059413","volume":"12","author":"EW Schafer","year":"1983","unstructured":"Schafer EW, Bocules WA, Hurlbut J (1983) The acute oral toxicity and hazard potential of 998 chemicals to one or more species of wild and domestic birds. Arch Environ Contam Toxicol 12:355\u2013382","journal-title":"Arch Environ Contam Toxicol"},{"key":"5442_CR34","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/brain\/121.5.967","volume":"121","author":"GL Sheean","year":"1998","unstructured":"Sheean GL, Murray NM, Rothwell JC, Miller DH, Thompson AJ (1998) An open-labelled clinical and electrophysiological study of 3,4-diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 121:967\u2013975","journal-title":"Brain"},{"key":"5442_CR35","unstructured":"Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C (2003) Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane database syst rev 2,CD001330"},{"key":"5442_CR36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s004150170262","volume":"248","author":"J Spatt","year":"2001","unstructured":"Spatt J, Chaix R, Mamoli B (2001) Epileptic and non-epileptic seizures in multiple sclerosis. J Neurol 248:2\u20139","journal-title":"J Neurol"},{"key":"5442_CR37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1212\/01.WNL.0000078893.41040.56","volume":"61","author":"M Strupp","year":"2003","unstructured":"Strupp M, Schuler O, Krafczyk S, Jahn K, Schautzer F, Battner U, Brandt T (2003) Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology 61:165\u2013170","journal-title":"Neurology"},{"key":"5442_CR38","first-page":"413","volume":"150","author":"MM Vohra","year":"1964","unstructured":"Vohra MM, Pradhan SN (1964) Pharmacology of 3,4-diaminopyridine. Arch Int Pharmacodyn Ther 150:413\u2013424","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"5442_CR39","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1021\/jm00327a006","volume":"17","author":"M Vohra","year":"1965","unstructured":"Vohra M, Pradhan SN, Jain PC et al (1965) Synthesis and structure-activity relationships of some aminopyridines, imidazopyridines, and triazolopyridines. J Med Chem 17:296\u2013304","journal-title":"J Med Chem"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-009-5442-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-009-5442-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-009-5442-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:12:55Z","timestamp":1559056375000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-009-5442-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,8]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["5442"],"URL":"https:\/\/doi.org\/10.1007\/s00415-009-5442-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,8]]}}}